5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Conditions

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Trial Timeline

Oct 1, 2011 → Mar 1, 2012

NCT ID

NCT01954615

About 5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F)

5 mg ACT-281959 prodrug formulation I (Group A) + 20 mg ACT-281959 prodrug formulation I (Group B) + ACT-281959 prodrug formulation I (Groups C to G doses to be defined) + ACT-281959 prodrug formulation II (Group G dose to be defined) + ACT-246475 (Group G dose to be defined) + Placebo (Groups A to F) is a phase 1 stage product being developed by Idorsia for Safety, Tolerability, Pharmacokinetics and Pharmacodynamics. The current trial status is completed. This product is registered under clinical trial identifier NCT01954615. Target conditions include Safety, Tolerability, Pharmacokinetics and Pharmacodynamics.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01954615	Phase 1	Completed	Oct 1, 2011	Mar 1, 2012	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Competing Products

20 competing products in Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

See all competitors

Product	Company	Stage	Hype Score
LPH-5 + Placebo	Biotrial	Phase 1	25
DS-1971 + placebo	Daiichi Sankyo	Phase 1	33
ASP7962 + Placebo	Astellas Pharma	Phase 1	33
ASP2151 + Valacyclovir + Placebo	Astellas Pharma	Phase 1	33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solution	AstraZeneca	Phase 1	33
Anifrolumab SC injection (300mg) + Anifrolumab IV infusion (300mg) + Anifrolumab SC infusion (600mg) + Anifrolumab placebo SC injection (300mg) + Anifrolumab placebo IV infusion (300mg) + Anifrolumab placebo SC infusion (600mg)	AstraZeneca	Phase 1	33
AZD7594 + Placebo to match	AstraZeneca	Phase 1	33
Anastrozole ODF + Arimidex tablet + Anastrozole ODF + Arimidex tablet	AstraZeneca	Phase 1	33
AZD4721 Solution + AZD4721 Placebo + AZD4721 Suspension	AstraZeneca	Phase 1	33
AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution	AstraZeneca	Phase 1	33
AZD3043	AstraZeneca	Phase 1	33
AZD8848 + Placebo to match AZD8848	AstraZeneca	Phase 1	33
AZD9567 Monohydrat + Placebo oral suspension/ Placebo capsule + Prednisolone	AstraZeneca	Phase 1	33
AZD7503 + Placebo	AstraZeneca	Phase 1	33
Fluad + Saline	Novartis	Approved	85
TBM100	Novartis	Approved	85
VIB9600 + Placebos	Amgen	Phase 1	32
Denosumab	Amgen	Phase 3	76
Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil	Akeso	Phase 2	51
HTL0018318 + Placebo oral capsule	Nxera Pharma	Phase 1	32

Other Products from Idorsia

Daridorexant + PlaceboApproved

Daridorexant 50 mg + PlaceboApproved

Aprocitentan 12.5 mg + Aprocitentan 25 mg + PlaceboPhase 3

LucerastatPhase 3

Clazosentan + PlaceboPhase 3